Advertisement

Dysphagia

, Volume 23, Issue 4, pp 406–410 | Cite as

Botulinum Toxin A Treatment of Cricopharyngeal Dysphagia After Subarachnoid Hemorrhage

  • Eike KrauseEmail author
  • Jörg Schirra
  • Robert Gürkov
Case Report

Abstract

Elevated muscular tone associated with spastic syndromes can cause excessive contractility at the upper esophageal sphincter and impede swallowing. A 47-year-old male patient with spasticity predominantly of the lower extremities after a subarachnoid hemorrhage suffered from severe dysphagia and chronic salivary aspiration. He was dependent on a cuffed tracheostomy tube and a percutaneous enterogastric feeding tube. Barium swallow and esophageal manometry revealed cricopharyngeal spasm, while laryngeal elevation and pharyngeal contractility were well preserved. We endoscopically injected 180 MU botulinum toxin A into the cricopharyngeus muscle. Two days post injection, swallowing function had improved and oral nutrition was possible. This improvement lasted for six weeks. After another injection 8 weeks later, an undesired diffusion into the hypopharynx occurred and manometry showed diminished contractility without amelioration of dysphagia. Botulinum toxin therapy of cricopharyngeal spasm improves swallowing function in a subgroup of patients with spastic syndromes. The therapeutic effect is of limited duration. Toxin diffusion into the pharynx should be avoided. Manometry is useful in planning and monitoring the therapy.

Keywords

Botulinum toxin Dysphagia Upper esophageal sphincter Manometry Spasticity Deglutition Deglutition disorders 

References

  1. 1.
    Clark HM. Neuromuscular treatments for speech and swallowing: a tutorial. Am J Speech Lang Pathol 2003;12(4):400–415.CrossRefPubMedGoogle Scholar
  2. 2.
    Alberty J, Oelerich M, Ludwig K, Hartmann S, Stoll K. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope 2000;110(7):1151–1156.CrossRefPubMedGoogle Scholar
  3. 3.
    Kahrilas PJ. Upper esophageal sphincter function during antegrade and retrograde transit. Am J Med 1997;103(5A):56S–60S.CrossRefPubMedGoogle Scholar
  4. 4.
    Cook IJ, Dodds WJ, Dantas RO, Massey B, Kern MK, Lang IM, Brasseur JG, Hogan WJ. Opening mechanisms of the human upper esophageal sphincter. Am J Physiol 1989;257:G748–G759.PubMedGoogle Scholar
  5. 5.
    Schmid H, Wolfensberger M, Augustiny N, Brühlmann W. Cricopharyngeal myotomy in the dysfunction of the pharyngoesophageal sphincter. HNO 1987;35:425–429 [in German].PubMedGoogle Scholar
  6. 6.
    Laskawi R, Roggenkämper P. Botulinumtoxin-Therapie im Kopf-Hals-Bereich. Urban & Vogel Verlag, 2. aktual. und erw. Auflage, 2004.Google Scholar
  7. 7.
    Schneider I, Thumfart WF, Pototschnig C, Engel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new noninvasive method. Ann Otol Rhinol Laryngol 1994;103:31–35.PubMedGoogle Scholar
  8. 8.
    Moerman MB. Cricopharyngeal botox injection: indications and technique. Curr Opin Otolaryngol Head Neck Surg 2006;14(6):431–436.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of OtorhinolaryngologyLudwig-Maximilians-UniversityMunichGermany
  2. 2.Department of Medicine IILudwig-Maximilians-UniversityMunichGermany

Personalised recommendations